The Effects of Systemic Isotretinoin Treatment on Adrenal Steroid and Sex Hormones Level in Severe Acne Vulgaris
NCT05903716 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40
Last updated 2023-06-15
Summary
Acne vulgaris is a chronic inflammatory skin disease involving the pilosebaceous unit, affecting approximately 95% of adolescents and young adults.
Follicular hyperkeratinization, increased sebum production, androgen hormones and inflammation play a role in the pathogenesis of acne. Androgens (Testosterone, DHEA-S and DHT) play a role in the development of acne, hypertrophy of the sebaceous glands and increased sebum production. Androgen receptors are located in the basal layer of the sebaceous glands keratinocytes and they are located in the outer sheath of the hair follicle. These receptors are responsible for the proliferative action of keratinocytes.
The relationship between androgen hormones and acne in women and prepubertal children is well known. Many studies have shown a strong association between acne and hyperandrogenism in women.
Systemic isotretinoin therapy can be used in patients with severe acne vulgaris who do not respond to topical and oral antibiotic treatments.
In recent studies, it has been shown that systemic isotretinoin used in acne treatment changes many hormones such as GnRH, FSH, LH, Estrogen, Progesterone, Testosterone, TSH, T4 and Prolactin and causes side effects such as menstrual irregularity and hirsutism.
However, data on the effect of oral isotretinoin on adrenal and sex hormones are contradictory.
In this study, it was aimed to evaluate the effect of oral isotretinoin on adrenal steroid and sex hormone levels and to compare it with a healthy control.
Isotretinoin treatment is started in acne vulgaris patients at a dose of 0.5-0.8mg/kg/day. The total cumulative dose is 120 mg/kg.
At baseline and at the 3rd month of isotretinoin treatment, 17-OH Progesterone, DHEA, DHEAS, Androstenedione, Aldosterone, Testosterone, Dihydrotestosterone, Estradiol, 17-OH Pregnenolone, Androsterone, Cortisol, Corticosterone, 11-Degesterone, 21, -Deoxycortisol, Pregnenolone, 11-Deoxycorticostreone hormones will be evaluated with LCMS/MS technique.
In addition, the FSH, LH, Prolactin, Estrogen, Testosterone, free testosterone, DHEA-s, SHBG, TSH, T4 hormone levels of the patients will be evaluated by ELISA method.
In the baseline 2nd, 3rd, 4th and 6th months of the treatment and 3 months after the treatment, the patients' height, weight, body mass index measurements, VAS scoring of patient treatment satisfaction, Global Acne Severity Score, Acne Quality of Life Score, and Modified Ferriman Gallwey Score for hirsutism will be recorded.
The side effects of isotretinoin such as menstrual irregularity, increased hair growth, and cheilitis, dryness of the oral mucosa, skin dryness, dermatitis seen in patients during treatment will be recorded.
\*Hormone tests were performed on 2th and 3rd days of menstruation
Conditions
- Acne Vulgaris
Interventions
- DIAGNOSTIC_TEST
-
Hormone
At baseline 17-OH Progesterone, DHEA, DHEAS, Androstenedione, Aldosterone, Testosterone, Dihydrotestosterone, Estradiol, 17-OH Pregnenolone, Androsterone, Cortisol, Corticosterone, 11-Degesterone, 21, -Deoxycortisol, Pregnenolone, 11-Deoxycorticostreone hormones will be evaluated.In addition, the FSH, LH, Prolactin, Estrogen, Testosterone, free testosterone, DHEA-s, SHBG, TSH, T4 hormone levels of the patients will be evaluated from all patients
- DRUG
-
Isotretinoin
İn the 3rd month of isotretinoin treatment, 17-OH Progesterone, DHEA, DHEAS, Androstenedione, Aldosterone, Testosterone, Dihydrotestosterone, Estradiol, 17-OH Pregnenolone, Androsterone, Cortisol, Corticosterone, 11-Degesterone, 21, -Deoxycortisol, Pregnenolone, 11-Deoxycorticostreone hormones will be evaluated.In addition, the FSH, LH, Prolactin, Estrogen, Testosterone, free testosterone, DHEA-s, SHBG, TSH, T4 hormone levels of the patients will be evaluated by ELISA method
Sponsors & Collaborators
-
Marmara University
lead OTHER
Eligibility
- Min Age
- 14 Years
- Max Age
- 20 Years
- Sex
- FEMALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2022-09-15
- Primary Completion
- 2023-06-30
- Completion
- 2023-06-30
Countries
- Turkey (Türkiye)
Study Locations
More Related Trials
-
Assessment of Serum Catestatin Level in Acne Vulgaris Patients
NCT07054398 ·Status: RECRUITING ·Phase: NA
-
Dry Eye Disease With Isotretinoin ISOTRETINOIN
NCT06725290 ·Status: NOT_YET_RECRUITING
-
Correlation Between Depression Scores and Serum NF-ĸB/NLRP3 Axis, Biotinidase, and HMGB After Treatment With Isotretinoin in Patients With Acne Vulgaris
NCT06242288 ·Status: COMPLETED ·Phase: PHASE3
-
Weekly Isotretinoin Therapy Study
NCT04594759 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
The Use of Teledermatology in the Treatment of Patients With Severe Acne on Isotretinoin
NCT03707236 ·Status: WITHDRAWN ·Phase: NA
-
Impact of Isotretinoin in Different Doses on Quality of Life
NCT05316675 ·Status: UNKNOWN ·Phase: PHASE4
-
Comparison Between Isotretinoin, Silymarin and Both in the Treatment of Acne Vulgaris
NCT05666765 ·Status: UNKNOWN ·Phase: PHASE4
-
Weekly Isotretinoin vs Tetracycline for Moderate Acne
NCT06225570 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma
NCT00939965 ·Status: UNKNOWN ·Phase: NA
-
The Influence of Peripheral Androgen Conversion at Women Adult Acne
NCT01850095 ·Status: UNKNOWN ·Phase: NA
-
Acne Remission Maintenance by Weekend Systemic Isotretinoin
NCT06451237 ·Status: COMPLETED ·Phase: PHASE3
-
Expert Consensus on the Use of Isotretinoin in Acne Vulgaris: A Delphi Study
NCT07296523 ·Status: ENROLLING_BY_INVITATION
-
Efficacy of Cosmetic Product RV3278B-OS0386 in the Maintenance Phase After Oral Isotretinoin Treatment of Adults Subjects With Facial Acne.
NCT07341659 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea
NCT01139749 ·Status: UNKNOWN ·Phase: PHASE4
-
Effect of Systemic Retinoic Acid Use on Micro Ribonucleic Acid (mRNA) Expression
NCT07142070 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Clinical Trial to Compare Oral Isotretinoin to Standard of Care in Moderate Acne Skin of Color Patients
NCT06447480 ·Status: RECRUITING ·Phase: PHASE3
-
Thyroid Dysfunction in Female Patients With Acne Vulgaris: [ Relation to Other Variables ]
NCT03602534 ·Status: UNKNOWN
-
Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment
NCT01727440 ·Status: COMPLETED
-
Efficacy, Safety Profile, and Post-Acne Sequelae of 0.025% Retinoic Acid Cream vs. 0.1% Adapalene Cream in Mild Acne Vulgaris in Fitzpatrick Skin Types III-V
NCT07015931 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer
NCT00002506 ·Status: COMPLETED ·Phase: PHASE2
-
Changes in PACAP, CGRP, and VIP Levels in Rosacea Patients on Systemic Isotretinoin and Their Association with Erythema
NCT06873087 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Oral Isotretinoin on Muscle Strength in Patients With Acne Vulgaris: A Prospective Controlled Study
NCT04626817 ·Status: COMPLETED ·Phase: NA
-
Proof of Concept Study to Investigate the Recurrence of Acne Post Isotretinoin
NCT00939133 ·Status: COMPLETED ·Phase: PHASE4
-
Isotretinoin in Preventing Skin Cancer
NCT00025012 ·Status: COMPLETED ·Phase: NA
-
A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV)
NCT04451330 ·Status: COMPLETED ·Phase: PHASE4